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Abstract
Background: Genome-wide association studies in Japanese populations recently identified common variants in the KCNQ1
gene to be associated with type 2 diabetes. We examined the association of these variants within KCNQ1 with type 2
diabetes in a Dutch population, investigated their effects on insulin secretion and metabolic traits and on the risk of
developing complications in type 2 diabetes patients.
Methodology: The KCNQ1 variants rs151290, rs2237892, and rs2237895 were genotyped in a total of 4620 type 2 diabetes
patients and 5285 healthy controls from the Netherlands. Data on macrovascular complications, nephropathy and
retinopathy were available in a subset of diabetic patients. Association between genotype and insulin secretion/action was
assessed in the additional sample of 335 individuals who underwent a hyperglycaemic clamp.
Principal Findings: We found that all the genotyped KCNQ1 variants were significantly associated with type 2 diabetes in
our Dutch population, and the association of rs151290 was the strongest (OR 1.20, 95% CI 1.07–1.35, p= 0.002). The risk C-
allele of rs151290 was nominally associated with reduced first-phase glucose-stimulated insulin secretion, while the non-risk
T-allele of rs2237892 was significantly correlated with increased second-phase glucose-stimulated insulin secretion
(p= 0.025 and 0.0016, respectively). In addition, the risk C-allele of rs2237892 was associated with higher LDL and total
cholesterol levels (p= 0.015 and 0.003, respectively). We found no evidence for an association of KCNQ1 with diabetic
complications.
Conclusions: Common variants in the KCNQ1 gene are associated with type 2 diabetes in a Dutch population, which can be
explained at least in part by an effect on insulin secretion. Furthermore, our data suggest that KCNQ1 is also associated with
lipid metabolism.
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Introduction
Recent genome-wide association (GWA) studies have provided
a first significant insight into the genetic architecture of type 2
diabetes, and to date, around 40 loci have been identified to be
robustly associated with the disease [1]. So far, the majority of
GWA scans have been performed in populations of European
descent [1], The first GWA studies in East Asians have recently
identified single nucleotide polymorphisms (SNPs) in a previously
unreported gene, KCNQ1, which were associated with type 2
diabetes susceptibility [2,3]. The original studies also confirmed
this finding in populations of European descent [2,3].
It is recognized, that in the pathophysiology of type 2 diabetes
both disturbances in insulin action (liver and muscle) and in insulin
secretion are early events [4] with additional factors such as age
itself [5]. Therefore, it is important to examine the association
between the KCNQ1 variants and metabolic traits to elucidate the
underlying diabetes-causing mechanisms.
In this study we aimed to investigate (1) the relationship of
specific KCNQ1 gene SNPs in the pathophysiology of type 2
diabetes by examining their association with metabolic traits and
insulin secretion during hyperglycemic clamps, and (2) whether
these SNPs relate to the risk of developing diabetes complications
and to the risk of mortality among type 2 diabetes patients of
Dutch origin.
Materials and Methods
Type 2 diabetes case-control sample description
We included 4,620 type 2 diabetes patients and 5,285 healthy
controls of Dutch Caucasian origin ascertained from various study
populations in the Netherlands: 1) the New Hoorn and Diabetes
Care System (DCS) West-Friesland studies: 1,969 patients with
type 2 diabetes and 1,951 controls with a normal glucose tolerance
[6,7,8]; 2) the Breda study: 569 type 2 diabetes patients and 920
healthy blood bank donors [9]; 3) the Zwolle Outpatient Diabetes
project Integrating Available Care (ZODIAC) study: 914 primary
care patients with type 2 diabetes [10]; 4) the European
Prospective Investigation Into Cancer and Nutrition-the Nether-
lands (EPIC-NL): 976 type 2 diabetes patients and 1,646 controls
[11,12]; 5) the Vlagtwedde/Vlaardingen cohort: 768 controls from
the general population [13]; 6) the Utrecht Diabetes Epidemiology
Study (UDES) study: 192 Dutch white individuals with type 2
diabetes. The ancestry in all studies except the EPIC-NL sample
was determined based on self-reported information. Detailed
characteristics are shown in Table S1.
The UDES population has not been described before: it was
collected from the population-based Pharmaco-Morbidity Record
Linkage System (PHARMO, www.pharmo.nl) linking drug-
dispensing histories from a representative sample of Dutch
community pharmacies to the national register of hospital
discharges (Landelijke Medische Registratie (LMR)) from 1985
onwards. A retrospective cohort study of new users of blood
glucose - lowering drugs (either oral hypoglycaemic agents or
insulin), who were 18 years or older was designed, and 1,609
patients were recruited through community pharmacies partici-
pating in PHARMO. Diagnosis of type 2 diabetes was confirmed
by self-reported information from the participants. We have
checked a small sample of 24 type 2 diabetes cases and 92% of
these could be confirmed according to the World Health
Organisation (WHO) criteria for diagnosing type 2 diabetes.
From these 1,609 patients, 255 took part in the study, returned the
questionnaire that had been sent to them, and donated blood for
various assessments and DNA retrieval. Laboratory measurements
included plasma total cholesterol, low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol, triglycer-
ides, fasting blood glucose, non-fasting blood glucose, and HbA1c.
Only Dutch white individuals were included in the present study
(n= 192).
All patients from studies 1–4 were diagnosed according to the
WHO criteria (2-hour plasma glucose levels .11.1 mmol l21 or
fasting plasma glucose levels $7.0 mmol l21).
Data on diabetic complications and on mortality in type
2 diabetes patients
The presence of macrovascular complications (n = 284), ne-
phropathy (n= 442), neuropathy (n = 333), and diabetic retinop-
athy (n = 465) was available in a subset of type 2 diabetes patients
from DCS West-Friesland, the ZODIAC and the EPIC-NL
studies (Table S2). [8,10,12]. A diagnosis of diabetic retinopathy
in the DCS West-Friesland was based on the examination of
fundus photography graded by an ophthalmologist according to
the EURODIAB Study grading system as described elsewhere [8].
A diagnosis of diabetic retinopathy in the ZODIAC cohort was
based on an ophthalmologist’s examination that demonstrated
microaneurysms, macular edema, or (pre-) proliferative retinop-
athy. In the EPIC-NL study data on diabetic complications was
collected during the ascertainment and verification of prevalent
and incident diabetes cases in the Dutch contributor to the EPIC
cohort. Diabetes was ascertained via self-report, linkage to registers
of hospital discharge diagnoses and a urinary glucose strip test.
Ascertained diabetes cases were verified against general practi-
tioner (GP) or pharmacist information using mailed questionnaires
[12]. The GP questionnaire contained 12 questions on diabetes.
The questions on in what year and which type of diabetes had
been diagnosed, on how the diagnosis was established, on
treatment during the first year after diagnosis and current
treatment (diet, oral glucose lowering medication, insulin), and
whether the patient suffered from long-term complications were
asked. When the GP was unknown, pharmacist information was
used to verify the diagnosis of diabetes. The pharmacist
questionnaire contained eight questions concerning use of diabetes
medication [12].
Data from the ZODIAC study on mortality were collected after
a follow-up period of 10 years in a prospective Zwolle cohort of
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type 2 diabetes patients by retrieving life status and cause of death
from records maintained by the hospital and the GPs [10].
Hyperglycaemic clamp study
Participants from three independent studies from the Nether-
lands were used: 138 impaired glucose tolerance (IGT) subjects
from the Hoorn study, 74 subjects (63 normal glucose tolerance
(NGT)/11 IGT) from the Utrecht clamp cohort and 123 twins and
sibs (116 NGT/7 IGT) from the Netherlands Twin Register
(NTR) [14,15]. The latter cohort is a family based twin study,
which includes 66 monozygotic, and 28 dizygotic twins as well as
29 of their nontwin sibs recruited from 50 families [15]. The
clinical characteristics of the study groups are given in Table S3.
Details of these study groups and the clamp procedure have
previously been described elsewhere [14,15].
All participants (n = 335) underwent a hyperglycaemic clamp at
10 mmol/l glucose for at least 2 h. First-phase insulin secretion
was determined as the sum of the insulin levels during the first
10 min of the clamp. Second-phase insulin secretion was
determined as the mean of the insulin levels during the last
40 min of the second hour of the clamp (80–120 min). The insulin
sensitivity index (ISI) was calculated by relating the glucose
infusion rate (M) to the plasma insulin concentration (I) during the
last 40 min of the second hour of the clamp (M/I). The disposition
index (DI) was calculated by multiplication of first-phase insulin
secretion and ISI in order to quantify insulin secretion in relation
to the ambient insulin sensitivity [15].
All study protocols were approved by local institutional review
boards or hospital medical ethics committees (the New Hoorn and
DCS West-Friesland studies were approved by the medical ethics
committee of the VU University Medical Center Amsterdam; the
Breda, EPIC-NL, and UDES studies were approved by the
Medical Ethics Committee of the University Medical Center
Utrecht; the ZODIAC study was approved by the local Medical
Ethical Committee of the Isala Clinics; the Vlagtwedde/Vlaardin-
gen study was approved by the Medical Ethics Committee of the
University Medical Center Groningen, the ‘clamp studies’ were
approved by the medical ethics committees of the VU University
Medical Center Amsterdam and the University Medical Center
Utrecht). All participants gave their written informed consent.
Genotyping
Based on the original GWA scans and the replication studies in
Europeans, we selected gene variants with a minor allele frequency
(MAF).5% - rs151290, rs2237892, and rs2237895 in the KCNQ1,
which were reported to be strongly associated with type 2 diabetes
in European population [2,3,16,17,18]. The two SNPs rs2237895
and rs2237892 showed the strongest association with T2D and
were replicated in European population in the original studies by
Unoki et al. and Yasuda et al., respectively [2,3]. The variant
rs151290 showed strong association in the third screening in the
original study by Yasuda et al. [3], and was also reported to be
associated with insulin secretion in a German population by
Mussig et al. [18].
These variants were genotyped in all the samples except the
EPIC-NL study samples using Taqman assays (Applied Biosys-
tems, Applied Biosystems, Nieuwerkerk a/d IJssel, The Nether-
lands) and were analyzed using a TaqMan 7900HT (Applied
Biosystems). The DNA samples were processed in 384-well plates.
Each plate contained 16 genotyping controls (4 duplicates of 4
different Centre d’Etude du Polymorphisme Humain (CEPH)
samples). There were no discordances in the genotypes of any of
the CEPH samples and the CEU data available from HapMap.
The genotype success rate was 95.6%, 97.6% and 98.2% for
rs151290, rs2237892, and rs2237895, respectively. For the
individuals from the EPIC-NL study, the genotypes data for the
two SNPs - rs2237892 and rs2237895, were available. The EPIC-
NL samples were genotyped using the Illumina IBC v.3 array (also
referred to as the CardioChip or the Human Cardiovascular
Disease [HumanCVD] BeadChip [Illumina] [19]). The genotyp-
ing information was not available for rs151290 because this SNP
was not included on the CardioChip. The rs2237892 and
rs2237895 SNPs were clustered into genotypes with the use of
the Illumina Beadstudio software and were subjected to quality
control filters at the sample (i.e. only samples with call rate .95%
and only not related and individuals of European ancestry were
included) and SNP levels (i.e. SNPs with a call rate ,95% or
HWE p,1026 were removed).
Statistical analysis
The genotype frequencies were tested for Hardy-Weinberg
equilibrium (HWE) by x2 analysis. In the genotyped samples from
the EPIC-NL study, pi-hat, a measure of identity by descent, was
calculated to exclude cryptic relatedness and duplicate samples (pi-
hat.0.2) via the method implemented in PLINK [20]; EIGEN-
STRAT method was used to compute principal component with
HapMap panels as reference standards to exclude the population
outliers [21].
To test for association of genotypes and type 2 diabetes and its
complications, genotype-based odds ratios (OR) with 95%
confidence intervals (CI) were calculated in the combined sample
of type 2 diabetes patients and controls using a logistic regression
model, with individuals homozygous for the non-risk allele as the
reference group. The risk and non-risk alleles were defined based
on the previous reports [2,3,16,17,18]. The association between
genotypes and metabolic traits (BMI, HbA1c, fasting glucose,
HDL- and LDL cholesterol, total cholesterol, triglyceride) was
determined using linear regression analysis. This analysis was
restricted to control individuals to avoid diabetes status or
treatment masking potential effects of the variants on these
phenotypic traits. All analyses were done under the additive model
and the presented p-values are adjusted for age, sex and study
center, with the continuous traits log-transformed prior to
statistical comparisons. The effect of the risk alleles on the
responses during hyperglycaemic clamping was examined by
calculating the b values for the risk allele with linear generalized
estimating equations, which takes into account the family
relatedness when computing the standard errors (i.e., in the twin
sample from the Netherlands Twin Register study). Only for
rs2237892 the non-risk allele was used for the latter calculations
since our sample did not have any homozygotes for the risk allele.
All outcome variables were log-transformed prior to analysis.
Analyses of hyperglycaemic clamp data were also adjusted for age,
sex, BMI, study center and glucose tolerance status. A Cox
proportional hazard model was used to assess association between
the SNPs and total mortality with correction for age and sex.
To account for the number of independent tests, a p-value of
,0.0033 (a=0.05/15) was considered statistically significant,
given independent tests for 15 outcomes (type 2 diabetes status, its
complications (i.e. retinopathy, nephropathy, neuropathy), meta-
bolic traits (i.e. (BMI, HbA1c, fasting glucose, HDL, LDL, total
cholesterol, triglyceride) and the parameters related with insulin
secretion). However, as this level is probably too stringent as a
Bonferroni correction assumes independency of the tests, which is
clearly not the case in this study, p-values between 0.05 and 0.0033
were considered nominally significant. All statistical analyses were
performed using the SPSS program, version 14.0 for Windows
(SPSS, Chicago, IL, USA).
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Power calculation was performed using Quanto software
(http://hydra.usc.edu/gxe/). Assuming a disease prevalence in
the Dutch population of 0.04 [6], our study had more than 95%
power to detect the ORs of 1.30, 1.29 and 1.24 reported by Unoki
et al. and Yasuda et al. for rs151290, rs2237892, and rs2237895,
respectively, with a significance level of 0.05 for the allele
frequencies of the risk allele of 0.79, 0.93, and 0.40, and assuming
a log-additive model [2,3].
Results
Effect of the KCNQ1 polymorphisms on type 2 diabetes
risk in Dutch population
We genotyped the KCNQ1 variants rs151290, rs2237892, and
rs2237895 in a total of 4,620 type 2 diabetes patients and 5,285
healthy controls. Baseline characteristics of the study population
are shown in Table 1. The controls were in Hardy-Weinberg
equilibrium (HWE) (x2 = 0.33, p=0.57 for rs151290, x2 = 3.21,
p=0.07 for rs2237892, and x2 = 0.09, p=0.77 for rs2237895).
Genotype and allele frequencies in both controls and type 2
diabetes cases are summarised in Table 2. In the control group
the observed MAF were 24%, 5%, and 41%, for rs151290,
rs2237892, and rs2237895, respectively, which are similar to the
MAF in the European population reported previously [2,3,18]. In
our sample, all three variants were associated with type 2 diabetes.
The risk alleles were identical to those in previous studies: the
major C-allele for rs151290 and for rs2237892, the minor C-allele
for rs2237895 [2,3,16,17,18]. The variant rs151290 showed the
strongest association with the disease (OR 1.20, 95% CI 1.07–
1.35, p=0.002, adjusted for age, sex and study center).
Effect of KCNQ1 polymorphisms on insulin secretion as
assessed with hyperglycaemic glucose clamps
To investigate potential mechanisms by which the variants in
KCNQ1 may contribute to type 2 diabetes susceptibility, we used
regression analysis to examine the effects of KCNQ1 genotypes on
first- and second-phase of glucose stimulated insulin secretion,
insulin sensitivity index (ISI) and disposition index (DI) in a sample
of non-diabetic individuals in whom hyperglycaemic clamp was
performed (Table 3). We found nominal association between the
C-allele of rs151290 and decreased insulin secretion during first-
phase and increased ISI (p=0.025 and p=0.006, adjusted for age,
sex, study center, BMI and glucose tolerance status, respectively)
as well as nominal relationship between the C-allele of rs2237895
and higher ISI values (p=0.034, adjusted for age, sex, study
center, BMI and glucose tolerance status). In addition, we
observed that carriers of the non-risk allele for rs2237892 had
significantly higher second phase insulin secretion and nominally
significant lower ISI compared to the homozygotes for the C-risk
allele (p=0.0016 and p=0.036, adjusted for age, sex, study center,
BMI and glucose tolerance status, respectively). None of the
KCNQ1 variants had an effect on the DI in our study.
Relationship of KCNQ1 polymorphisms with metabolic
parameters
Next, we investigated whether the KCNQ1 polymorphisms
influenced relevant clinical parameters, such as BMI, HbA1c,
fasting glucose, HDL, LDL, total cholesterol and triglycerides, in
Table 1. Clinical characteristics of the study participants.
Trait
T2D patients
(n =4620) Controls (n =5285)
n Mean ± SD n Mean ± SD
Male (%) 4616 1999 (43.3) 5272 2209 (41.9
Age-at-study (years) 4617 64.3610.6 5266 51.1610.1
Age at diagnosis (years) 3497 58.7611.6 - -
BMI (kg/m2) 4550 29.464.9 4349 26.063.8
HbA1c (%) 4370 7.161.3 3565 5.460.4
Fasting glucose 2496 8.362.3 1951 5.360.4
HDL-cholesterol (mmol/l) 4187 1.260.3 3553 1.460.4
LDL-cholesterol (mmol/l) 2746 2.860.9 3545 3.260.9
Total cholesterol (mmol/l) 4226 5.161.2 3571 5.461.0
Triglyceride (mmol/l) 4232 2.061.3 3564 1.460.9
The data are presented as mean 6 SD. BMI: Body Mass Index. HbA1c:
haemoglobin A1c. HDL: high density lipoprotein. LDL: low density lipoprotein.
T2D: type 2 diabetes.
doi:10.1371/journal.pone.0032148.t001
Table 2. Association of the KCNQ1 variants with type 2 diabetes in the Dutch population.
SNP Allele data Genotype distribution (%) p-valuea,b
Group
Major/minor
allele RAF OR (95% CI) p-valuea 11 12 22
rs151290
T2D C/A 0.78 1.20 (1.07–1.35) 0.002 2081 (60.2) 1220 (35.3) 153 (4.4) 0.003
Control 0.76 2045 (58.3) 1258 (35.9) 204 (5.8)
rs2237892
T2D C/T 0.96 1.16 (0.97–1.40) 0.11 4149 (92.0) 348 (7.7) 14 (0.3) 0.002
Control 0.95 4638 (90.0) 507 (9.8) 7 (0.1)
rs2237895
T2D A/C 0.43 1.09 (1.00–1.17) 0.035 1522 (33.5) 2158 (47.4) 869 (19.1) 0.006
Control 0.41 1803 (34.8) 2516 (48.6) 863 (16.7)
aAdjusted for age, sex and study center.
bp-value for the additive model.
For each variant the C-allele is the risk allele for type 2 diabetes as identified by previous studies. RAF: risk allele frequency. T2D: type 2 diabetes.
doi:10.1371/journal.pone.0032148.t002
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non-diabetic individuals (Table 4). Under an additive genetic
model, the diabetes risk allele of rs2237892 was nominally
associated with increased LDL level and significantly associated
with a higher level of total cholesterol (p=0.015 and p=0.003,
adjusted for age, sex and study center, respectively). In addition,
carriers of the C-risk allele of rs2237895 had nominally
significantly higher HbA1c levels (p=0.036, adjusted for age, sex
and study center).
Relationship of KCNQ1 polymorphisms with diabetes
complications and mortality
We further investigated whether there was an association
between the KCNQ1 gene SNPs and various type 2 diabetes
complications and mortality. We did not observe any association
of KCNQ1 SNPs with diabetic complications, although there was a
trend of the homozygous carriers of the risk C-allele of rs2237895
being more frequent among the diabetic patients with retinopathy
compared to the patients without it (22.5 vs. 19.2%, p=0.06,
adjusted for age, sex, study and duration of type 2 diabetes).
Data on mortality were collected after a follow-up period of 10
years in the ZODIAC study; the characteristics of the study
population are shown in Table S4. After a median follow-up
period of 9.5 years, a total of 358 (39%) patients had died, of these
146 (41%) had died from cardiovascular disease and 82 (23%)
deaths were cancer-related. The cause of death was known for 336
(97.6%) patients. All the baseline characteristics - age at baseline,
gender, duration of diabetes, smoking status, BMI, systolic blood
pressure, HbA1c, serum creatinine, total cholesterol to HDL-
cholesterol ratio, and albuminuria creatinine ratio – were not
significantly different in the groups according to the KCNQ1 SNPs.
In our study, there was no evidence of association for the KCNQ1
SNPs with mortality. The age and sex adjusted HR for patients
carrying one or both risk alleles compared to non-carriers were
HR 0.97 (95% CI 0.56–1.66, p -value 0.91) and HR 0.94 (95% CI
0.75–1.18, p –value 0.56); HR 0.98 (95% CI 0.14–7.03, p -value
0.97) and HR 1.10 (95% CI 0.74–1.64, p -value 0.64); HR 1.10
(95% CI 0.81–1.49, p -value 0.32) and HR 0.92 (95% CI 0.68–
1.23, p -value 0.56) for rs151290, rs2237892, rs2237895,
respectively.
Discussion
Two independent GWA studies recently performed in Japanese
populations identified KCNQ1 as a type 2 diabetes susceptibility
gene [2,3]. We here confirm the association of the KCNQ1
common variants with an increased risk of type 2 diabetes in a
Dutch population. The individuals carrying the same at-risk alleles
C, as reported in the Japanese studies [2,3], had a modestly
increased risk of developing type 2 diabetes, with a population
attributable risk from 0.6% to 4.3%. These results are also
consistent with previous studies performed in Caucasian popula-
tions [2,3,16,17,22,23]. In the present study, we demonstrate in a
large cohort of subjects having undergone hyperglycaemic glucose
clamps that the risk allele of the KCNQ1 SNP is significantly
associated with reduced glucose-stimulated second-phase insulin
secretion. In addition, we report a significant association of KCNQ1
variants with impaired lipid parameters. We could not find any
significant relationship of the risk alleles of the KCNQ1 gene with
type 2 diabetes complications or mortality.
The variants rs151290, rs2237892, and rs2237895 are located
in intron 15 of the KCNQ1 gene on chromosome 11p15, encoding
the pore-forming alpha subunit of the I(Ks) channel, a voltage-
gated potassium channel that is expressed in a number of tissues,
notably, the heart, pancreas, kidneys and intestine [2,3]. The
encoded protein plays a role in the electrical depolarisation of the
cell membrane in the heart and presumably in pancreas beta cells.
It is likely to be involved in insulin secretion, although there are
other possibilities, such as secretory processes in incretin (GLP-1
and/or GIP) -producing cells [2,3]. Our results provide compel-
ling evidence that the KCNQ1 rs2237892 variant is associated with
impaired second-phase insulin secretion. Moreover, these data
confirm the observations from the previous studies in which the
relationship between the type 2 diabetes risk alleles in KCNQ1 and
reduced levels of various measures of insulin secretion have been
reported [17,18,22,24], and hence, supports the hypothesis on a
Table 3. Effect of KCNQ1 variants rs151290, rs2237892 and rs2237895 on beta-cell function as assessed with hyperglycaemic
clamp.
SNP Genotype (N)
1st phase insulin
response (pmol/l)
2nd phase insulin
response (pmol/l)
ISI (mmol N min21 N kg21 N
pmol/l21) DI (mmol N min21 N kg21)
rs151290
AA (19)
CA (90) b (sem)a 20.046 (0.020) 20.029 (0.021) +0.059 (0.021) +0.011 (0.022)
CC (226) p-valuea 0.025 0.16 0.0061 0.63
rs2237892
TT (0)
CT (28) b (sem)a +0.052 (0.036) +0.126 (0.040) 20.091 (0.044) 20.028 (0.039)
CC (301) p-valuea 0.15 0.0016 0.036 0.47
rs2237895
AA (86)
AC (180) b (sem)a 20.024 (0.021) 20.029 (0.022) +0.047 (0.022) +0.026 (0.019)
CC (63) p-valuea 0.26 0.19 0.034 0.18
aAdjusted for glucose tolerance status (NGT/IGT), study center, age, gender and BMI.
All variables were log-transformed before analysis. p-values were computed for different additive models using linear generalized estimating equations (GEE) which
takes into account the family relatedness when computing the standard errors. Alleles in bold are the risk alleles for type 2 diabetes identified by previous studies.
DI, disposition index; IGT, impaired glucose tolerance; ISI, insulin sensitivity index; ND, not determined; NGT, normal glucose tolerance.
doi:10.1371/journal.pone.0032148.t003
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potential link between KCNQ1 and impaired beta-cell function
[2,3,17,18,22,23,24,25,26].
The importance of the investigation of the various aspects of
insulin secretion was highlighted previously [27]. It is thought that
first phase insulin secretion is reflecting the rapid recruitment and
release of insulin granules from the readily releasable pool, while
second phase is due to the release of granules located further away
from release site (reserve pool) and due to (new) insulin synthesis
[28]. In the present study, we used the hyperglycaemic clamp
technique, generally considered to be the gold standard for
quantification of first- and second-phase insulin secretion to
measure beta-cell function [29]. We show, for the first time, an
association between a variant in the KCNQ1 gene (rs2237892) and
second-phase insulin secretion. This observation indicates that
KCNQ1 might play a role in second-phase insulin secretion
suggesting a novel potential link between KCNQ1 and impaired
beta-cell function via the decreased release of newly formed insulin
following glucose stimulation. It is worth noting, that it appears
from previous studies from others and ourselves that the majority
of the known beta-cell loci influence mainly the first-phase insulin
secretion [17,18,30,31,32]. Although we did not detect a
significant effect of KCNQ1 on first-phase insulin secretion, we
observed decreased insulin secretion among the C-allele carriers of
rs151290, which is in agreement with the recent study by Mussing
et al. [18]. Also, Holmkvist et al. reported the association between
the KCNQ1 gene and reduced estimates of first-phase insulin
release [17]. Both above-mentioned studies used data obtained
during oral glucose tolerance test [17,18]. Our data derived from
the hyperglycaemic clamp extends these finding and suggests that
KCNQ1 may have an effect regarding second phase secretion and
therefore may have additional effects apart from early, rapid
recruitment and exocytosis of insulin granules after glucose
stimulation. In addition, there was a surprising trend of the
association between all three risk alleles and higher ISI values.
Interestingly, Boini et al. have recently shown that insulin
sensitivity is strikingly increased in the KCNQ1 knockout mouse,
which agrees with our results [33]. Thus, although the KCNQ1
gene is primarily a candidate gene for impaired insulin secretion,
its effect on tissue-specific insulin-sensitivity independent of
changes in insulin secretion is plausible.
In addition, we found a significant association between the type
2 diabetes risk allele of rs2237892 and higher level of total
cholesterol and a trend towards increased level of LDL among the
carriers of the same allele. Also, we observed a lower level of HDL
Table 4. Effect of KCNQ1 variants rs151290, rs2237892 and rs2237895 on quantitative metabolic traits in non-diabetic individuals.
rs151290 p-valuea,b
Genotype (N) AA (204) AC (1252) CC (2035)
BMI (kg/m2) 26.563.6 26.063.8 26.363.9 0.20
HbA1c (%) 5.3060.23 5.3360.26 5.3360.27 0.52
Fasting glucose (mmol/l) 5.3160.36 5.3160.38 5.3060.38 0.82
HDL cholesterol (mmol/l) 1.6260.40 1.5660.44 1.5560.41 0.07
LDL cholesterol (mmol/l) 3.2460.83 3.3160.87 3.3160.87 0.65
Total cholesterol (mmol/l) 5.4460.93 5.4660.95 5.4460.98 0.76
Triglyceride (mmol/l) 1.2960.60 1.3060.69 1.3160.73 0.85
rs2237892
Genotype (N) TT (7) CT (507) CC (4623)
BMI (kg/m2) 23.563.2 26.163.9 26.063.9 0.46
HbA1c (%) 5.1860.14 5.4060.51 5.3960.39 0.71
Fasting glucose (mmol/l) 5.0760.06 5.2760.40 5.3160.37 0.29
HDL cholesterol (mmol/l) 1.3360.29 1.4160.40 1.4360.41 0.24
LDL cholesterol (mmol/l) 3.0060.84 3.0860.80 3.2360.89 0.015
Total cholesterol (mmol/l) 5.1160.92 5.2260.96 5.4061.02 0.003
Triglyceride (mmol/l) 1.5760.70 1.3960.81 1.4260.86 0.79
rs2237895
Genotype (N) AA (1797) AC (2509) CC (857)
BMI (kg/m2) 26.063.8 25.963.9 26.163.8 0.99
HbA1c (%) 5.3760.40 5.4060.40 5.4160.41 0.036
Fasting glucose (mmol/l) 5.3060.37 5.3160.38 5.2960.36 0.90
HDL cholesterol (mmol/l) 1.4460.41 1.4260.42 1.4260.40 0.82
LDL cholesterol (mmol/l) 3.2060.87 3.2160.87 3.2560.91 0.21
Total cholesterol (mmol/l) 5.3661.00 5.3861.00 5.4561.07 0.14
Triglyceride (mmol/l) 1.3960.86 1.4160.81 1.4860.96 0.17
aAdjusted for age, sex and study center.
bp-value for the additive model.
The data are presented as mean6SD. All variables were log-transformed before analysis. Alleles in bold are the risk alleles for type 2 diabetes identified by previous
studies. BMI: Body Mass Index. HbA1c: haemoglobin A1c (glucose bound to haemoglobin). HDL: high density lipoprotein. LDL: low density lipoprotein.
doi:10.1371/journal.pone.0032148.t004
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in the carriers of the type 2 diabetes risk allele of rs151290 variant
than in non-carriers. Interestingly, Chen et al. have recently
reported the relationship of KCNQ1 variants with higher level of
triglycerides (i.e. also rs2237892) and lower levels of HDL [34].
Although the mechanisms behind the observed associations are
not clear, taken together, these data suggest that KCNQ1 may have
an effect on lipid metabolism. Further studies are needed to
elucidate the underlying molecular mechanisms.
In the present study, we found no significant evidence for an
association of KCNQ1 with diabetic complications or mortality in
type 2 diabetes patients. Recently, Ohshige et al. reported that
KCNQ1 might be a potential susceptibility gene for diabetic
nephropathy in a Japanese population [35]. In our sample, we
could not confirm that finding. These results could be due to the
relatively small sample of the patients with nephropathy in our
study (there were 442 patients in our study versus 1545 diabetic
patients with overt nephropathy in the study by Ohshige et al.
[35]). Next, the association with nephropathy was not easy to
detect due to differences in risk-allele frequency (33% in Japanese
versus 5% in European) of the rs2237897 variant associated with
nephropathy (r2 = 0.6 with rs2237892) [35]. Our study had 20%
power at p=0.05 to detect the OR of 1.22 reported by Ohshige et
al. [35] assuming prevalence of nephropathy of 0.40 among type 2
diabetes patients [36] and an additive model. In addition, we
cannot exclude a proportion of patients with diabetic nephropathy
in the reference sample. Therefore, additional replication attempts
in larger studies with detailed information on the complications
status are warranted.
It needs to be noted that in the current study we used control
subjects younger than the patients. Thus, we cannot exclude that
some of these individuals may develop diabetes in later life.
However, this would result in slight reduction in statistical power
and also in the ORs and would lead to the underestimation of the
‘‘true’’ effects of the KCNQ1 variants on susceptibility to T2D in our
study. Next, the individuals in the hyperglycaemic clamp study were
younger than the type 2 diabetes patients used in the association
analysis. Also, the mean age of the participants in the groups of the
clamp study was different. To test the effect of age on the
relationship between the KCNQ1 variants and insulin secretion, we
performed an additional analysis in the different clamp study
groups. The results of these analyses were similar to the observations
in the whole clamp sample (Table S5). Another limitation of the
current study that needs to be taken into account is the lack of
correction for population stratification. Since the ethnicity was
determined based on self-reported information (except for the
EPIC-NL study), we cannot rule out presence of the participants of
non-Dutch Caucasian origin in our study. However, as the same
alleles are the risk alleles for type 2 diabetes in populations of
different ancestries (the minor allele for rs2237895, the major allele
for both rs151290 and rs2237892) [2,3], and the non-Caucasian
participants are very likely to be present in both control and patients
groups, that will have had only a minor effect on the results in our
study. In addition, the MAFs in our study were similar to the MAFs
reported in European populations [2,3,16,17,18].
Finally, it is still unclear whether the variants rs151290,
rs2237892, and rs2237895 located in intron 15 of the KCNQ1
gene directly affect the gene expression or are in strong linkage
disequilibrium with a causal polymorphism in KCNQ1 or a
neighbouring gene. Also, it was recently shown that one of the type
2 diabetes association signals maps to a part of the KCNQ1
sequence which also encodes a different transcript (KCNQ1OT1)
which is known to be an key regulator of other genes in the region,
including KCNQ1 itself, but also CDKN1C, a gene already heavily
implicated in islet development [23].
In conclusion, we here show that common variation in the
KCNQ1 gene affect second-phase insulin secretion and confirm the
association of the gene with type 2 diabetes in a Dutch population.
We also found that the variants in the KCNQ1 gene may have an
effect on lipid metabolism. These results provide new insight into
the complex pathogenesis of diabetes.
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participants from different studies. The data are presented
as mean6SD. BMI: Body Mass Index. HbA1c: haemoglobin A1c
(glucose bound to haemoglobin). HDL: high density lipoprotein.
T2D: type 2 diabetes. NA: not applicable.
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interquartile range for non-normally distributed data or %.
* P,0.05, ** P,0.01, ***P,0.001, tested with Student’s t-test
or Mann-Whitney U as appropriate.
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Table S5 Effect of KCNQ1 variants rs151290, rs2237892
and rs2237895 on beta-cell function as assessed with
hyperglycaemic clamp. Analysis was adjusted for glucose
tolerance status (NGT/IGT), study center, age, gender and BMI.
All variables were log-transformed before analysis. p-values were
computed for different additive models using linear generalized
estimating equations (GEE) which takes into account the family
relatedness when computing the standard errors. Alleles in bold
are the risk alleles for type 2 diabetes identified by previous studies.
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insulin sensitivity index; ND, not determined; NGT, normal
glucose tolerance.
(DOC)
Acknowledgments
We thank all the participants. We thank J. Senior and H. Snieder for
critically reading the manuscript.
Author Contributions
Conceived and designed the experiments: JVV ER MHH LMTH.
Performed the experiments: JVV ER LMTH. Analyzed the data: JVV
ER LMTH. Contributed reagents/materials/analysis tools: TWVH
GWDL ER NK HJGB OHK AD CCVD CW HMB JMD EVTR GN
LMCW HZ EJB CCE FB NCO YTVDS DEG AMWS DLVDA AMS
EME MD MHHK DIB EJD GW PES. Wrote the paper: JVV.
Contributed to the interpretation of the data and to the writing of the
manuscript: TWVH ER MHH LMTH. Provided critical comments on the
manuscript: GWDL NK JMD EVTR LMCW HZ NCOM YTVDS
AMWS AMS.
KCNQ1 and Altered Insulin Secretion
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32148
References
1. McCarthy MI (2011) Dorothy Hodgkin Lecture 2010. From hype to hope? A
journey through the genetics of Type 2 diabetes. Diabet Med 28: 132–140.
2. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. (2008) SNPs
in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and
European populations. Nat Genet 40: 1098–1102.
3. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, et al. (2008) Variants in
KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet
40: 1092–1097.
4. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles
of pathogenesis and therapy. Lancet 365: 1333–1346.
5. Szoke E, Shrayyef MZ, Messing S, Woerle HJ, van Haeften TW, et al. (2008)
Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell
function in individuals with impaired glucose tolerance. Diabetes Care 31:
539–543.
6. van ’t Riet E, Alssema M, Rijkelijkhuizen JM, Kostense PJ, Nijpels G, et al.
(2010) Relationship between A1C and glucose levels in the general Dutch
population: the new Hoorn study. Diabetes Care 33: 61–66.
7. Welschen LM, van Oppen P, Dekker JM, Bouter LM, Stalman WA, et al. (2007)
The effectiveness of adding cognitive behavioural therapy aimed at changing
lifestyle to managed diabetes care for patients with type 2 diabetes: design of a
randomised controlled trial. BMC Public Health 7: 74.
8. Zavrelova H, Hoekstra T, Alssema M, Welschen LM, Nijpels G, et al. (2010)
Progression and regression: distinct developmental patterns of diabetic
retinopathy in patients with type 2 diabetes treated in the diabetes care system
west-friesland, the Netherlands. Diabetes Care 34: 867–872.
9. van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van
Haeften TW, et al. (2007) Association of variants of transcription factor 7-like 2
(TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort.
Diabetologia 50: 59–62.
10. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, et al.
(2003) Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a
prospective population-based study in The Netherlands (ZODIAC-1).
Eur J Epidemiol 18: 793–800.
11. Beulens JW, Monninkhof EM, Verschuren WM, van der Schouw YT, Smit J,
et al. (2010) Cohort profile: the EPIC-NL study. Int J Epidemiol 39: 1170–1178.
12. Sluijs I, van der AD, Beulens JW, Spijkerman AM, Ros MM, et al. (2010)
Ascertainment and verification of diabetes in the EPIC-NL study. Neth J Med
68: 333–339.
13. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, et al.
(2005) A disintegrin and metalloprotease 33 polymorphisms and lung function
decline in the general population. Am J Respir Crit Care Med 172: 329–333.
14. t Hart LM, Nijpels G, Dekker JM, Maassen JA, Heine RJ, et al. (2002)
Variations in insulin secretion in carriers of gene variants in IRS-1 and -2.
Diabetes 51: 884–887.
15. Simonis-Bik AM, Nijpels G, van Haeften TW, Houwing-Duistermaat JJ,
Boomsma DI, et al. (2010) Gene variants in the novel type 2 diabetes loci
CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect
different aspects of pancreatic beta-cell function. Diabetes 59: 293–301.
16. Grallert H, Herder C, Marzi C, Meisinger C, Wichmann HE, et al. (2010)
Association of genetic variation in KCNQ1 with type 2 diabetes in the KORA
surveys. Horm Metab Res 42: 149–151.
17. Holmkvist J, Banasik K, Andersen G, Unoki H, Jensen TS, et al. (2009) The type
2 diabetes associated minor allele of rs2237895 KCNQ1 associates with reduced
insulin release following an oral glucose load. PLoS One 4: e5872.
18. Mussig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, et al. (2009)
Association of type 2 diabetes candidate polymorphisms in KCNQ1 with
incretin and insulin secretion. Diabetes 58: 1715–1720.
19. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, et al. (2008)
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP
array for large-scale genomic association studies. PLoS One 3: e3583.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 38: 904–909.
22. Jonsson A, Isomaa B, Tuomi T, Taneera J, Salehi A, et al. (2009) A variant in
the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin
secretion. Diabetes 58: 2409–2413.
23. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve
type 2 diabetes susceptibility loci identified through large-scale association
analysis. Nat Genet 42: 579–589.
24. Tan JT, Nurbaya S, Gardner D, Ye S, Tai ES, et al. (2009) Genetic variation in
KCNQ1 associates with fasting glucose and beta-cell function: a study of 3,734
subjects comprising three ethnicities living in Singapore. Diabetes 58:
1445–1449.
25. Been LF, Ralhan S, Wander GS, Mehra NK, Singh JR, et al. (2011) Variants in
KCNQ1 increase type II diabetes susceptibility in South Asians: A study of
3,310 subjects from India and the US. BMC Med Genet 12: 18.
26. Qi Q, Li H, Loos RJ, Liu C, Wu Y, et al. (2009) Common variants in KCNQ1
are associated with type 2 diabetes and impaired fasting glucose in a Chinese
Han population. Hum Mol Genet 18: 3508–3515.
27. Ingelsson E, Langenberg C, Hivert MF, Prokopenko I, Lyssenko V, et al. (2010)
Detailed physiologic characterization reveals diverse mechanisms for novel
genetic Loci regulating glucose and insulin metabolism in humans. Diabetes 59:
1266–1275.
28. Rorsman P, Eliasson L, Renstrom E, Gromada J, Barg S, et al. (2000) The Cell
Physiology of Biphasic Insulin Secretion. News Physiol Sci 15: 72–77.
29. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method
for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223.
30. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, et al. (2008)
Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during
hyperglycaemic clamps. Diabetologia 51: 1659–1663.
31. Stancakova A, Kuulasmaa T, Paananen J, Jackson AU, Bonnycastle LL, et al.
(2009) Association of 18 confirmed susceptibility loci for type 2 diabetes with
indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327
nondiabetic Finnish men. Diabetes 58: 2129–2136.
32. t Hart LM, Simonis-Bik AM, Nijpels G, van Haeften TW, Schafer SA, et al.
(2010) Combined risk allele score of eight type 2 diabetes genes is associated with
reduced first-phase glucose-stimulated insulin secretion during hyperglycemic
clamps. Diabetes 59: 287–292.
33. Boini KM, Graf D, Hennige AM, Koka S, Kempe DS, et al. (2009) Enhanced
insulin sensitivity of gene targeted mice lacking functional KCNQ1. Am J Physiol
Regul Integr Comp Physiol.
34. Chen Z, Yin Q, Ma G, Qian Q (2010) KCNQ1 gene polymorphisms are
associated with lipid parameters in a Chinese Han population. Cardiovasc
Diabetol 9: 35.
35. Ohshige T, Tanaka Y, Araki S, Babazono T, Toyoda M, et al. (2010) A single
nucleotide polymorphism in KCNQ1 is associated with susceptibility to diabetic
nephropathy in japanese subjects with type 2 diabetes. Diabetes Care 33:
842–846.
36. Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H, et al. (2008) Gene
and protein markers of diabetic nephropathy. Nephrol Dial Transplant 23:
792–799.
KCNQ1 and Altered Insulin Secretion
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32148
